VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Rosenthal on Treatment Strategies for Indolent Lymphomas

Allison C. Rosenthal, DO
Published: Thursday, Oct 20, 2016



Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses some of the treatment strategies for patients with indolent lymphomas in an interview during the 2016 OncLive State of the Science Summit on Treatment of Hematologic Malignancies.

Currently, first-line treatment for patients with indolent lymphomas involve rituximab (Rituxan) or rituximab plus chemotherapy, Rosenthal explains. These strategies, however, are not effective for all patients, especially those who have comorbidities.

Some oral targeted therapies that are becoming available could be better options for patients; however, longer follow-up is needed with them to ensure their efficacy in patients for long-term use.


Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses some of the treatment strategies for patients with indolent lymphomas in an interview during the 2016 OncLive State of the Science Summit on Treatment of Hematologic Malignancies.

Currently, first-line treatment for patients with indolent lymphomas involve rituximab (Rituxan) or rituximab plus chemotherapy, Rosenthal explains. These strategies, however, are not effective for all patients, especially those who have comorbidities.

Some oral targeted therapies that are becoming available could be better options for patients; however, longer follow-up is needed with them to ensure their efficacy in patients for long-term use.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x